GlassScriptPhysician profile
Soha Dolatabadi
NPI 1992806277
$457,718.66
in general payments reported to CMS, 2019-2025
31 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $21K · 2022: $62K · 2023: $117K · 2024: $126K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Consulting Fee: $50K · Travel and Lodging: $35K · Food and Beverage: $22K · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $241,939.00 |
| Consulting Fee | $49,550.00 |
| Travel and Lodging | $34,984.18 |
| Food and Beverage | $21,566.22 |
| Education | $348.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $195,337.35 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $130,247.60 | 2019-2025 | Simponi Aria, Tremfya |
| Glaxosmithkline, LLC. | $38,674.49 | 2019-2025 | Benlysta, Nucala |
| Abbvie INC. | $32,636.86 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $25,959.63 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $19,440.25 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $6,301.20 | 2019-2023 | Tremfya, Stelara, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $2,396.91 | 2020-2025 | Acthar |
| Lilly USA, LLC | $1,223.30 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $707.50 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $591.16 | 2020-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $567.51 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $560.87 | 2019-2023 | Krystexxa |
| Pfizer INC. | $479.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.21 | 2022-2025 | Ofev |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $450.65 | 2019 | |
| Ani Pharmaceuticals, INC. | $402.47 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Alexion Pharmaceuticals, INC. | $379.44 | 2023-2025 | Strensiq |
| Hikma Pharmaceuticals USA | $224.96 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $157.63 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| E.R. Squibb & Sons, L.L.C. | $120.82 | 2019-2021 | |
| Genzyme Corporation | $104.16 | 2020-2025 | |
| Fidia Pharma USA INC. | $102.71 | 2021-2022 | |
| Sobi, INC | $55.54 | 2022 | |
| Genentech USA, INC. | $27.34 | 2025 | Gazyva |
| Fresenius Kabi USA, LLC | $25.67 | 2023 | Idacio |
| Tonix Medicines, INC. | $23.95 | 2025 | Tonmya |
| Celltrion USA INC. | $18.78 | 2023 | Yuflyma |
| Sun Pharmaceutical Industries INC. | $18.26 | 2020 | |
| Alvogen INC | $11.43 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soha Dolatabadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.